Rene J. Goldberg Arnold PharmD President & CEO Arnold Consultancy & Technology LLC
ReneJ.GoldbergArnoldPharmD ISPORDistanceLearningProgram
LearningObjectives
BytheendoftheIntroductiontoPharmacoeconomics moduleyouwillbeableto:
y y y
LearningObjectives(contd.)
y
Introduction
y y
Canthehealthsystemsupporttheadditionalcostfor eachlifesavedifthenewdrugisbothmorecostly andmoreeffectivethanprevioustherapies? Ifanewdrugordeviceislesscostly,butless effective,thanexistingtherapies,howmuchofa diminutioninefficacycansociety/payers/patients withstandinordertosavemoney? Howmuchmoneymustbesavedinordertomakeit "costeffective"toacceptareductioninefficacyover existingstrategies?
UseofPharmacoeconomics/ CostEffectivenessAnalyses
y y y y
BenefitsfromPEAnalysisofHealth CarePrograms
y Intangiblebenefits(valueofhealthperseto individualconsumer) y Futurehealthcostsavoided y Increasedproductiveoutputduetoimprovedhealth status y Useofevidencebasedmedicinetomakebestchoices forpopulationandindividuals
OutcomesAssessmentand Pharmacoeconomics
y Outcomesassessment:determinationofendresultofuse ofhealthcaretechnology y Finitesocietalresourcesrequireconsiderationof opportunitycosts(valueofalternativeusesofthose resources) y Healthcarereformhasrequiredmethodstoevaluate economicandsocietalvalueofgoodsandservices y Pharmacoeconomicsevaluatesvalueformoneyexpended onhealthcaretechnologies
ObjectivesofPharmacoeconomics
y Applicationofeconomicprinciplestodrug therapyinterventions(preventionand/or cure) y Researchthatidentifies,measures,and comparesthecosts(resourcesconsumed) andconsequencesofpharmaceutical productsandservices Improveindividualandpublichealth outcomes Provideformorerationaldecisionmaking
o o o
Stepsinevaluatingtypeofanalysis
y Efficacy:optimalcircumstances y Effectiveness:usualcircumstances y Efficiency:costeffectiveness Comparisonwithalternative therapy/therapies Requiresconsiderationofcoststobe included,perspective,timeframe, effectivenessmetric,discountrate, assumptions Diseaseendpointsassessedbyindicesof therapeuticoutcome
10
InfluenceofCompliancewith MedicationonCostEffectiveness
DBP Full Partial Compliance Compliance ($/QALY) ($/QALY)
$4,850 $9,880
$10,500 $20,400
Kozma CM, Reeder CE, Schulz RM: Economic, clinical and humanistic outcome: A planning model for pharmacoeconomic research. Clin Ther 15:1121-1132, 1993.
11
Questions
y Isthetreatmenteffective? y Whatwillitcost? y Howdothegainscomparewiththecosts? Typically,onechoosestheoptionwiththeleastcost perunitofmeasuregained Representedbyratioofcosttoeffectiveness(C:E) Calledcosteffectivenessanalysis(CEA)
12
TypesofCEA
y Costminimizationanalysis(CMA) Determinescostsassumingequivalent benefits Maybepresentedascostconsequence y Costbenefitanalysis(CBA) Measuresbenefitinmonetaryunits Difficulttovalue,e.g.,alife y Costeffectivenessanalysis(CEA) y Costutilityanalysis(CUA) Incorporatesqualityoflifeadjustments intoeffectivenessmetric
13
DefinitionofUtilities
y Quantifiedpreferencesforspecifichealthstates
14
ExpressionofUtility
y Utilitymeasuresyieldasinglevaluethatreflectsoverall qualityoflife(QoL) y Preferenceweightedmeasureusedtoproducepointin timeexpressionofwellbeing y 1.0(forasymptomaticfullfunction) y 0(fordeath) y UsedtoimpartQoL componenttoaneffectivenessvalue, suchaslifeyearsgained,toestablishQALYs
15
FrameworkforDetermining Costs
y y y y y
16
Cost/QALY Comparisons
17
DirectandIndirectCost
y Directmedicalandnonmedicalcosts
Medical:Relatedtoprovidingmedicalservices,e.g.,hospitalcare,
18
Consequences
y Monetarybenefits y Effectiveness:yearsoflifesaved,hospitalizations averted,complicationfreeepisodes,etc. y Utilitymeasurements:qualityadjustedlifeyears (QALYs)
19
AverageandMarginal(Incremental) CostEffectiveness
y AverageCostEffectiveness =resourcesconsumedperunitofoutput
y
Averagecostisderivedbydividingtotalcostbyvolumeor quantityofoutput
20
DecisionMakinginPE Analysis
More Effective More Costly Trade-off Less Effective Reject (dominant) Trade-off
Less Costly
Accept (dominant)
21
Perspective
y Societalvs payervs patient y NHSandothernationalized payersystemssuggest societalperspective;benefitinQALYs y Shorttermoutcomes;employersponsoredvs countrysponsored
y
ExamplesofbenefitsheremightbeMIavoidedor complicationfreeepisodes
22
PopulationSegmentation
y Developingcountries y Age y Race(antihypertensiveagentapprovedonlyfor AfricanAmericanpatients) y Gender(WeinsteinandStason CVmodel1) y Healthsystem(e.g.,presentstateofscreening)
Weinstein MC, Stason WB (1985). Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annu Rev Public Health, 6, 41-63.
23
Discounting
y Futurecostsandeffectsarediscounted y Positiverateoftimepreference y Prefer: y Receivedollarsnow y Payoutdollarslater y PV=FCxDF(n,r)
24
SensitivityAnalysis
y Analysisofuncertainvaluesaroundkey variables
25
Uncertainty
y Parameter y Structural
26
Implications
y Giventhattheprocessofestimating subgroupspecificinputparametersusually involvesreducingsamplesize,itisevenmore importanttoassesstheimplicationsof parameteruncertaintyfully.
27
CEAReportingFormats
y Journalarticles y Policydecisions
28
CEAReportingFormats(elements)
y y y y y y y
29
CEAReportingFormats(elements, cont.)
y y y y
30
31
CaseStudy:HPVVaccineCEA
y GoldieSJ,Kohli M,Grima D,etal. Projectedclinicalbenefitsand
costeffectivenessofahumanpapillomavirus 16/18vaccine.JNatl CancerInst.2004;96(8):60415. y Goldieandcolleaguesdevelopedacostutilitymodeltoevaluate cancerincidenceandmortality,lifetimecosts,lifeexpectancyand incrementalcosteffectivenessratiosprojectedtobeassociatedwith cervicalcancerandhumanpapillomavirus (HPV)vaccineinthe preventionofcervicalcancer.Thiscasestudywillbeusedasan exampleoftheuseofCEAinmedicaldecisionmaking.
32
33
Summary
y Ratioofcosttoeffectiveness y Evaluatesadditionalcostforadditionalunitof effectiveness y CEAmaybeusedtomakepolicydecisions amongcompetingtherapieswithfixed resourcesavailable
34
References
1. ArnoldR. Useofinteractivesoftwareinmedicaldecisionmaking.In: Ekins S,ed.ComputerApplicationsinPharmaceuticalResearchand Development.Hoboken:JohnWiley&Sons,Inc.;2006. 2. DrummondM,Sculpher M,TorranceG,O'BrienB,Stoddart G. MethodsfortheEconomicEvaluationofHealthCareProgrammes.3rd ed Oxford:OxfordUniversityPress;2007. 3. ArnoldRJ. Costeffectivenessanalysis:shoulditberequiredfordrug registrationandbeyond?DrugDiscov Today.2007;12(2122):9605. 4. GoldieSJ,Kohli M,Grima D,etal. Projectedclinicalbenefitsand costeffectivenessofahumanpapillomavirus 16/18vaccine.JNatl CancerInst.2004;96(8):60415.
Rene J. Goldberg Arnold, PharmD, iDLP 35
References
y Detsky AS,Laupacis A. Relevanceofcosteffectivenessanalysisto
cliniciansandpolicymakers.JAMA.2007;298(2):221224. y Rascati K.EssentialsofPharmacoeconomics;Philadelphia:Lippincott Williams&Wilkins;2008. y GoldbergArnoldR. Healtheconomicconsiderationsin cardiovasculardrugutilization.In:Frishman W,Sonnenblick E,eds. CardiovascularPharmacotherapeutics.2nded.NewYork:McGraw Hill,Inc.;2003:43. y GoldMR.CosteffectivenessinHealthandMedicine;Oxford:Oxford UniversityPress:1996.
36
References
y Muennig P,KhanK.DesigningandConductingCostEffectiveness
37